Schwab US Dividend Equity ETF ( $SCHD ) has fallen by 2.93% in the past week. It has experienced a 5-day net outflow of $235.03 million.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Abbvie has seen a positive shift in its stock outlook, with Piper Sandler raising its price target to $284 and maintaining an Overweight rating. This optimism is driven by settlements related to Rinvoq and strong performance across its commercial portfolio. Additionally, Abbvie announced positive results from its Phase 2 ELATE trial, which evaluated the efficacy of onabotulinumtoxinA for treating upper limb essential tremor, meeting all primary and secondary endpoints. However, the company anticipates a $1.50 per share unfavorable impact in Q3 due to milestone expenses.
- Amgen Inc has launched AmgenNow, a direct-to-consumer platform offering a significant 60% discount on its cholesterol-reducing drug, Repatha. This move aligns with President Trump’s push for lower drug prices, although it was not part of a government deal. Despite the discount, Amgen’s stock has not seen a positive reaction, with shares trending lower. Analysts maintain a Moderate Buy consensus with a price target suggesting a potential 10% upside.